Related Experiment Video

Updated: May 9, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome

Myo Nyein Aung1, Wattana Leowattana, Khine Nwe Win

  • 1Department of Public Health, Graduate School of Medicine, Juntendo University, Tokyo, Japan.

Journal of Infection in Developing Countries
|July 17, 2013
PubMed

Insights

Predictors of chronic hepatitis B (CHB) treatment success were identified. HBeAg negativity and early ALT normalization predict better outcomes on nucleos(t)ide analogue therapy, not initial viral load.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Chronic hepatitis B (CHB) is a prevalent global infectious disease with complex clinical progression.
  • Nucleos(t)ide analogues (NA) are standard treatments for CHB, particularly in Southeast Asia.
  • Composite treatment outcomes are crucial but rarely predicted epidemiologically in CHB management.

Purpose of the Study:

  • To compare composite treatment outcomes in CHB patients with low versus high baseline viral loads.
  • To identify predictors of composite treatment outcomes in CHB patients receiving NA therapy.

Main Methods:

  • A retrospective cohort study involving 95 CHB patients treated with NA for one year.
  • Composite outcome: undetectable HBV DNA, normalized ALT, and HBeAg clearance (if applicable).
  • Multinomial logistic regression analyzed predictors of treatment response.

Main Results:

  • Complete composite outcome achieved by 52% of patients with viral load < 6.5 log10 copies/mL vs. 31% with viral load ≥ 6.5 log10 copies/mL.
  • HBeAg negativity (aRRR=11.1) and ALT normalization within 6 months (aRRR=6.7) predicted successful outcomes.
  • ALT elevation >1.5x normal (40 IU/mL) predicted incomplete response (aRRR=6.2).

Conclusions:

  • Routine clinical markers, excluding pre-treatment viral load, effectively predict composite CHB outcomes.
  • HBeAg status and early ALT normalization are key indicators for NA therapy success in CHB.
Abstract

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...